Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm	Recruiting	Phase 2	2025-09-30		NCT07199296

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
First Affiliated Hospital of Wenzhou Medical University	117
Fujian Medical University Union Hospital	108
Huadong Hospital	23
Qilu Hospital of Shandong University	249
Ruijin Hospital	454
The First Affiliated Hospital of Anhui Medical University	85
The Third Xiangya Hospital of Central South University	75

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Ruijin Hospital	Shanghai	China	8